Intrapersonal HbA1c variability and the risk of progression of nephropathy in patients with Type2 diabetes

Diabetic Medicine

Volumn 29, Issue 12, 2012, Pages 1562-1566

  Rodriguez Segade S ^a   Rodriguez J ^a   Garcia Lopez J M ^a   Casanueva, F F ^a,b   Camina F ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b The Physiopathology of Obesity and Nutrition Biomedical Research Network Consortium   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; HEMOGLOBIN A1C; INSULIN; LIPID;

ADULT; ARTICLE; BODY MASS; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETINOPATHY; RISK FACTOR; SMOKING;

ALBUMINURIA; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SPAIN;

EID: 84869118723     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03767.x     Document Type: Article

References (16)

1. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2010; 33: S11-S61.
2. European Diabetes Policy Group. A desk-top guide to Type2 diabetes mellitus. Diabet Med 1999; 16: 716-730.
3. The Royal College of General Practitioners Effective Clinical Practice Unit. Clinical Guidelines for Type2 Diabetes Mellitus: Management of Blood Glucose. 2005. Available at http://www.nice.org.uk/nicemedia/live/10911/28998/28998.pdf Last accesed 30 November 2011.
4. Siegelaar SE, Holleman F, Hoekstra JBL, DeVries H. Glucose variability; does it matter?Endocr Rev 2010; 31: 171-182.
5. Service FJ, O'Brien PC. The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetologia 2001; 44: 1215-1220.
6. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type1 diabetes. Diabetes Care 2006; 29: 1486-1490.
7. 1c in the prediction of cardiovascular disease in type1 diabetes. Diabetologia 2008; 51: 365-371.
8. Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type1 diabetes: data from the DCCT. Diabetes Care 2008; 31: 2198-2202.
9. Wadén J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH. A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type1 diabetes. Diabetes 2009; 58: 2649-2655.
10. 1c are associated with a higher incidence of cardiovascular disease in Japanese patients with type2 diabetes. J Diabetes Invest 2012; 3: 148-155.
11. The Diabetes Control and Complications Trial Research Group. The association between glycemic exposure and long-term diabetic complications. Diabetes 1995; 44: 968-983.
12. 1c in human blood and the National Standardization Schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004; 50: 166-174.
13. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type2 diabetes (UKPDS33). Lancet 1998; 352: 837-853.
14. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. Ten-year follow-up of intensive glucose control in type2 diabetes. N Engl J Med 2008; 359: 1577-1589.
15. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type2 diabetes. J Am Med Assoc 2006; 295: 1681-1687.
16. Wentholt I, Kulik W, Michels R, Hoekstra J, De Vries J. Glucose fluctuations and activation of oxidative stress in patients with type1 diabetes. Diabetologia 2008; 51: 183-190.